报告名称: 本周医药板块上涨1.78%，诺诚健华坦昔妥单抗获批上市报告类型: 行业报告报告日期: 20250526研究员: 吴明华,陈玥桦行业: 医药投资评级：强于大市(维持)【内容摘要】本周申万医药生物板块涨幅为1.78%，跑赢沪深300指数1.96个百分点，在31个申万一级行业涨跌幅中排名第1位。二级子板块中，化学制药上涨3.58%；生物制品上涨1.74%；医疗服务上涨1.42%；医药商业上涨...
Source Link报告名称: 本周医药板块上涨1.78%，诺诚健华坦昔妥单抗获批上市报告类型: 行业报告报告日期: 20250526研究员: 吴明华,陈玥桦行业: 医药投资评级：强于大市(维持)【内容摘要】本周申万医药生物板块涨幅为1.78%，跑赢沪深300指数1.96个百分点，在31个申万一级行业涨跌幅中排名第1位。二级子板块中，化学制药上涨3.58%；生物制品上涨1.74%；医疗服务上涨1.42%；医药商业上涨...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.